Comparing Cryolife (CRY) & Interpace Diagnostics Group (IDXG)
Cryolife (NASDAQ: IDXG) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
This table compares Cryolife and Interpace Diagnostics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-71.14%||-34.58%||-25.64%|
68.9% of Cryolife shares are owned by institutional investors. Comparatively, 12.5% of Interpace Diagnostics Group shares are owned by institutional investors. 4.0% of Cryolife shares are owned by insiders. Comparatively, 2.8% of Interpace Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Cryolife has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Cryolife and Interpace Diagnostics Group, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||4||0||3.00|
Cryolife currently has a consensus target price of $31.33, indicating a potential downside of 9.96%. Interpace Diagnostics Group has a consensus target price of $3.19, indicating a potential upside of 119.83%. Given Interpace Diagnostics Group’s higher possible upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Cryolife.
Earnings and Valuation
This table compares Cryolife and Interpace Diagnostics Group’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cryolife||$189.70 million||6.75||$3.70 million||$0.40||87.00|
|Interpace Diagnostics Group||$15.90 million||2.57||-$12.21 million||($0.81)||-1.79|
Cryolife has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Cryolife, indicating that it is currently the more affordable of the two stocks.
Cryolife beats Interpace Diagnostics Group on 9 of the 12 factors compared between the two stocks.
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.